Darmerica, LLC
Has Darmerica, LLC received an FDA warning letter about GLP-1 drugs?
Yes. FDA issued Darmerica, LLC a warning letter naming retatrutide and cagrilintide, dated Dec 8, 2025, with the FDA subject line “CGMP/Active Pharmaceutical Ingredient (API)/Adulterated/Misbranded.”
FDA records in this index name Darmerica, LLC on Dec 8, 2025.
- Type named in FDA records
- API manufacturer
- FDA warning letters
- 1
- Drug recall reports
- 0
- Drugs named
- Retatrutide, Cagrilintide
- Latest record
- Dec 8, 2025
FDA warning letters
| Later letters FDA lists | Letter | |||
|---|---|---|---|---|
| Dec 8, 2025 | CGMP/Active Pharmaceutical Ingredient (API)/Adulterated/Misbranded | Retatrutide, Cagrilintide | None listed by FDA as of Nov 15, 2026 | fda.gov |
A warning letter states FDA’s view when it was issued; it is not a court finding, and the company may have responded since. The later-letters column repeats what FDA’s warning letter index lists for each letter.
FDA’s summary excerpts
- Dec 8, 2025: … of drugs lacking adequate directions for use You received retatrutide from your supplier, (b)(4) , FEI (b)(4) . Retatrutide is a GLP-1 API that is not identified as an … human drugs under section 503A of the FD&C Act even though retatrutide is not eligible for use in compounding under … Full letter
Drug recalls
No openFDA drug recall reports in this index.
FDA NDC listings
FDA’s NDC Directory files, read Nov 15, 2026, list 3 products naming liraglutide, semaglutide and tirzepatide under the labeler name “DARMERICA, LLC”, matched to this company page by exact name. Marketing categories as FDA gives them: BULK INGREDIENT (3).
| 71052-126 | Not given | Liraglutide | POWDER | Not given | 1 kg/kg | BULK INGREDIENT | May 10, 2023 | None given | Dec 31, 2026 | Unfinished drugs |
| 71052-695 | Not given | Semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Apr 25, 2023 | None given | Dec 31, 2027 | Unfinished drugs |
| 71052-167 | Not given | Tirzepatide | POWDER | Not given | 1 g/g | BULK INGREDIENT | May 2, 2023 | None given | Dec 31, 2027 | Unfinished drugs |
FDA says: “Assignment of an NDC number does not in any way denote FDA approval of the product.” All GLP-1 NDC listings.
This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.
Sources
- FDA warning letter, Dec 8, 2025
- FDA warning letters (fda.gov full-text search)
- FDA National Drug Code Directory (download files)
- FDA: NDC product file definitions
- openFDA drug NDC endpoint (count cross-check)
Records last pulled Nov 15, 2026. Every entry links to the original public record.